Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2007

Array BioPharma Earns Milestone from AstraZeneca

  • AstraZeneca dosed the first patient in a Phase I trial of Array BioPharma’s anticancer candidate. The milestone triggered a $2-million payment to Array BioPharma.

    ARRY-704 (AZD8330) is potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. ARRY-704 has shown tumor suppressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung, and breast cancers, according to Array BioPharma.

    In December 2003, Array partnered the oncology portion of its MEK program for co-development and commercialization with AstraZeneca. The collaboration included R&D of additional clinical candidates, which resulted in the selection of ARRY-704 in December 2005.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »